Beyond The Numbers: 7 Analysts Discuss Quest Diagnostics Stock
Portfolio Pulse from Benzinga Insights
Analysts have mixed views on Quest Diagnostics (NYSE:DGX), with recent ratings ranging from bullish to bearish. Over the last quarter, 7 analysts provided ratings, showing a shift towards a more neutral stance in the last 30 days. The average 12-month price target for DGX has been raised to $146.57, indicating a 4.91% increase from the previous target of $139.71. Despite a -7.68% decline in revenue over the past 3 months, Quest Diagnostics maintains strong financial indicators such as a high net margin of 9.72% and an ROE of 3.52%. The company's debt-to-equity ratio is also below industry norms at 0.76.
February 02, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Quest Diagnostics has seen a shift in analyst sentiment, with a more neutral outlook and an increased 12-month price target. Despite recent revenue challenges, the company's strong financial health is highlighted by its net margin, ROE, and manageable debt levels.
The increase in the 12-month price target for DGX, despite a recent revenue decline, suggests analysts see potential for recovery or growth based on the company's strong financial indicators. The shift towards a more neutral stance reflects caution but the overall positive financial health and the raised target price indicate a potential upside for the stock.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100